T-1249

T-1249 Trial Suspended: Formulation Woes Blamed (December 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
T-1249 Retains Potent Short-Term Antiviral Activity in Patients Who Have Failed a Regimen Containing T-20 (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
New Anti-HIV Therapies: Other Fusion Inhibitors (January 2003)
[Archived Article]
To read PDF, click here.
From Project Inform
Cool Your Jets: T-1249 Development Slows Down (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors and Antiretroviral History Do Not Affect Virologic Response to T-1249 (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Fusion Inhibitors (September/October 1999)
[Archived Article]
T-20 (Pentafuside) and T-1249.
In GMHC Treatment Issues, from Gay Men's Health Crisis

More Most Viewed Articles

HIV Tools You Can Use

Track Your CD4 Count, Viral Load and More: Use TheBody.com's Health Tracker

TheBody.com's Facebook, Widgets, RSS Feeds and Twitter
Are You at Risk for HIV? Take Our Quiz!
U.S. AS0 Finder U.S. ASO Listings
International ASOs
Find a Therapist or
Psychologist in Your Area

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.